BIOMAT Database Logo BIOMAT Database Logo

Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. 2014

Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Federal University of Rio de Janeiro, P.O. Box 68024, 21944-971 Rio de Janeiro, RJ, Brazil(1); Graduate Program of Chemistry (PGQu), Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Novel 2-chloro-4-anilino-quinazolines designed as EGFR and VEGFR-2 dual inhibitors were synthesized and evaluated for inhibitory effects. EGFR and VEGFR-2 are validated targets in cancer therapy and combined inhibition might be synergistic for both antitumor activity and resistance prevention. The biological data obtained proved the potential of 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors, highlighting compound 8o, which was approximately 7-fold more potent on VEGFR-2 and approximately 11-fold more potent on EGFR compared to the prototype 7. SAR and docking studies allowed the identification of pharmacophoric groups for both kinases and demonstrated the importance of a hydrogen bond donor at the para position of the aniline moiety for interaction with conserved Glu and Asp amino acids in EGFR and VEGFR-2 binding sites.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D040301 Vascular Endothelial Growth Factor Receptor-2 A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF. VEGFR-2,Fetal Liver Kinase-1,Flk-1 Protein,Flk-1 Receptor Tyrosine Kinase,KDR Tyrosine Kinase,Kinase Insert Domain Receptor,VEGF Receptor Flk-1,VEGF Receptor KDR,Fetal Liver Kinase 1,Flk 1 Protein,Flk 1 Receptor Tyrosine Kinase,Flk-1, VEGF Receptor,KDR, VEGF Receptor,Tyrosine Kinase, KDR,VEGF Receptor Flk 1,Vascular Endothelial Growth Factor Receptor 2
D066246 ErbB Receptors A family of structurally related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS. EGF Receptor,Epidermal Growth Factor Receptor,Epidermal Growth Factor Receptor Family Protein,Epidermal Growth Factor Receptor Protein-Tyrosine Kinase,ErbB Receptor,HER Family Receptor,Receptor, EGF,Receptor, Epidermal Growth Factor,Receptor, TGF-alpha,Receptor, Transforming-Growth Factor alpha,Receptor, Urogastrone,Receptors, Epidermal Growth Factor-Urogastrone,TGF-alpha Receptor,Transforming Growth Factor alpha Receptor,Urogastrone Receptor,c-erbB-1 Protein,erbB-1 Proto-Oncogene Protein,EGF Receptors,Epidermal Growth Factor Receptor Family Proteins,Epidermal Growth Factor Receptor Kinase,HER Family Receptors,Proto-oncogene c-ErbB-1 Protein,Receptor Tyrosine-protein Kinase erbB-1,Receptor, ErbB-1,Receptors, Epidermal Growth Factor,Epidermal Growth Factor Receptor Protein Tyrosine Kinase,ErbB-1 Receptor,Family Receptor, HER,Family Receptors, HER,Proto oncogene c ErbB 1 Protein,Proto-Oncogene Protein, erbB-1,Receptor Tyrosine protein Kinase erbB 1,Receptor, ErbB,Receptor, ErbB 1,Receptor, HER Family,Receptor, TGF alpha,Receptor, Transforming Growth Factor alpha,Receptors, EGF,Receptors, Epidermal Growth Factor Urogastrone,Receptors, ErbB,Receptors, HER Family,c erbB 1 Protein,c-ErbB-1 Protein, Proto-oncogene,erbB 1 Proto Oncogene Protein

Related Publications

Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors.
January 2019, Frontiers in chemistry,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
November 2019, European journal of medicinal chemistry,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
February 2016, European journal of medicinal chemistry,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors.
October 2013, Bioorganic & medicinal chemistry letters,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
January 2017, European journal of medicinal chemistry,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
December 2017, Molecules (Basel, Switzerland),
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.
January 2012, Bioorganic & medicinal chemistry,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
December 2019, Journal of enzyme inhibition and medicinal chemistry,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
August 2011, Bioorganic & medicinal chemistry,
Maria Letícia de Castro Barbosa, and Lídia Moreira Lima, and Roberta Tesch, and Carlos Mauricio R Sant'Anna, and Frank Totzke, and Michael H G Kubbutat, and Christoph Schächtele, and Stefan A Laufer, and Eliezer J Barreiro
Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
June 2022, Bioorganic chemistry,
Copied contents to your clipboard!